Holen Sie sich die Stockscreener-App
66.61
2.55%
-1.6965
Schlusskurs vom Vortag:
$68.31
Offen:
$67.86
24-Stunden-Volumen:
186.80K
Relative Volume:
0.16
Marktkapitalisierung:
$5.29B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-11.21
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-0.76%
1M Leistung:
+1.84%
6M Leistung:
+33.27%
1J Leistung:
+64.49%
1-Tages-Spanne:
$66.10
$69.23
1-Wochen-Bereich:
$66.00
$69.88
52-Wochen-Spanne:
$35.95
$69.88
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
66.64 | 5.43B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.18 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.68 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
827.86 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
What To Expect From PTC Therapeutics Inc (PTCT) Q3 2025 Earnings - GuruFocus
How PTC Therapeutics Inc. stock compares to growth peersDividend Hike & Safe Capital Growth Plans - newser.com
Detecting support and resistance levels for PTC Therapeutics Inc.2025 Winners & Losers & Verified Swing Trading Watchlists - newser.com
How to read the order book for PTC Therapeutics Inc.Weekly Earnings Recap & Real-Time Market Sentiment Alerts - newser.com
Wolverine Asset Management LLC Trims Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stake Lessened by Pinnacle Associates Ltd. - MarketBeat
How PTC Therapeutics Inc. stock benefits from global expansion2025 Volume Leaders & Verified Entry Point Signals - newser.com
PTC Therapeutics, Inc. $PTCT Shares Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Is PTC Therapeutics Inc. stock a top pick in earnings season2025 Performance Recap & Advanced Swing Trade Entry Plans - newser.com
Brighton Jones LLC Invests $226,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
Can PTC Therapeutics Inc. stock reach $100 price targetWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Published on: 2025-11-02 01:56:33 - newser.com
Is PTC Therapeutics Inc. (BH3) stock safe for risk averse investorsJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN
PTC Therapeutics (NASDAQ:PTCT) Director Sells $1,088,787.00 in Stock - MarketBeat
PTC Therapeutics Hits New 52-Week High of $69.88, Up 81.1% - Markets Mojo
Why PTC Therapeutics Inc. (BH3) stock is trending on social media2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-01 00:56:06 - newser.com
Insider Sell: Emma Reeve Sells 15,666 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics Inc expected to post a loss of $1.37 a shareEarnings Preview - TradingView
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares - Investing.com Australia
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares By Investing.com - Investing.com South Africa
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighWhat's Next? - MarketBeat
Ptc Therapeutics stock hits 52-week high at 69.53 USD By Investing.com - Investing.com Australia
How Investors May Respond To PTC Therapeutics (PTCT) Analysts' Optimism on Sephience Launch Momentum - Sahm
2025-10-31 | PTC Therapeutics to Participate at Upcoming Investor Conferences | NDAQ:PTCT | Press Release - Stockhouse
PTC Therapeutics Inc. stock prediction for this weekWeekly Trend Recap & Low Risk Entry Point Guides - newser.com
Will PTC Therapeutics Inc. (BH3) stock attract long term capital inflowsJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
PTC Therapeutics (NASDAQ:PTCT) NASDAQ Composite Leads Biotech - Kalkine Media
How to forecast PTC Therapeutics Inc. trends using time seriesWall Street Watch & Technical Entry and Exit Alerts - newser.com
Ptc Therapeutics stock hits 52-week high at 69.53 USD - Investing.com
How Recent Developments Are Shaping the PTC Therapeutics Investment Story - Yahoo Finance
PTC Therapeutics (PTCT) to Release Earnings on Tuesday - MarketBeat
Published on: 2025-10-29 06:46:31 - newser.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Allianz Asset Management GmbH - MarketBeat
Sector ETF performance correlation with PTC Therapeutics Inc.July 2025 Patterns & Weekly High Momentum Picks - newser.com
Jefferies Maintains PTC Therapeutics (PTCT) Buy Recommendation - Nasdaq
Huntington’s Disease | Clinical Landscape, Key Companies, Therapeutic Assessment, Treatment Algorithms, and Pipeline Insights – featuring leading players such as Hoffmann-La Roche, PTC Therapeutics, A - Barchart.com
PD-1 and PD-L1 Inhibitors Clinical Landscape, Key Companies, Therapeutic Evaluation, Treatment Approaches, and Pipeline Insights | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals - Barchart.com
Bevacizumab: Clinical Overview, Key Companies, Therapeutic Insights, Treatment Strategies, and Pipeline Analysis | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG B - Barchart.com
Published on: 2025-10-28 14:58:18 - fcp.pa.gov.br
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 - Insider Monkey
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - sharewise.com
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):